Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C/D)
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: capecitabine and trastuzumab|DRUG: vinorelbine and trastuzumab
Sponsor: Fudan University